Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.

Trial Profile

Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Telaprevir (Primary) ; Amprenavir; Atazanavir; Darunavir; Raltegravir; Tenofovir
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top